The Trump administration is positioning for what critics are calling a five-alarm fire for medical research, with plans to tighten political control over the National Institutes of Health. This isn't a budget squabble. It is a structural power grab that could reshape how federal science is funded and directed, sidelining peer review and empowering political appointees to set research priorities. If successful, the move would chill the very independence that makes American biomedical research the envy of the world. While that fight unfolds in Washington, the public is already seeing the consequences of weakened public health infrastructure. Measles cases have hit a 30-year high, and experts now say a specific group of adults may need a booster — a stark reminder that diseases we thought conquered can roar back when vigilance slips.

Meanwhile, an entirely different kind of health crisis is brewing in the courts and clinics. Lawsuits are piling up against Eli Lilly and Novo Nordisk as patients accuse popular GLP-1 drugs like Ozempic and Zepbound of causing permanent blindness. The cases are rare but disturbing, and they underscore how quickly blockbuster drugs can face existential liability questions when side effects emerge post-market. Separately, a new study reports that strokes are rising among younger adults, a trend driven by metabolic disease and lifestyle factors that demands a prevention rethink. On a more promising front, male contraceptives could hit pharmacies within five years, potentially shifting the burden of family planning. The real takeaway across all these stories: whether it’s political interference in science, resurgent infectious disease, or unpredicted drug harms, the systems we trust to protect our health are under strain from every direction.